SCHEMBL4986451

SCHEMBL4986451

Cc1ccc(S(=O)(=O)NCC(N)c2ccccc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 4/20 0.79
TP53 P04637 4/20 0.58
MAPT P10636 4/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
CYP1A2 P05177 2/20 0.57
CYP3A4 P08684 2/20 0.57
ATM Q13315 2/20 0.57
LMNA P02545 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
GAA P10253 2/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
CA12 O43570 2/20 0.57
CA9 Q16790 2/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27807197 1.00 GBA1 (0.79) GBA1TP53MAPTMEN1KMT2A
SCHEMBL12879312 1.00 GBA1 (0.79) GBA1TP53MAPTMEN1KMT2A
SCHEMBL4986251 0.89 GBA1 (1.00) GBA1TP53MAPTMEN1KMT2A
SCHEMBL28384728 0.85 GBA1 (0.79) GBA1TP53MAPTMEN1KMT2A
SCHEMBL28392275 0.85 GBA1 (0.79) GBA1TP53MAPTMEN1KMT2A
SCHEMBL17793668 0.82 TP53 (0.58) GBA1TP53MAPTMEN1KMT2A
SCHEMBL25196007 0.81 GBA1 (0.64) GBA1MAPTMEN1KMT2ACYP1A2
SCHEMBL20193352 0.81 GBA1 (0.73) GBA1MAPTMEN1KMT2ALMNA
SCHEMBL8200065 0.81 MAPT (0.67) GBA1TP53MAPTMEN1KMT2A
SCHEMBL27850983 0.79 CA9 (0.61) GBA1TP53MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7393958-B2 Triamide-substituted heterobicyclic compounds PFIZER, INC. (US) 2008-07-01 US disclosed
US-7368573-B2 Triamide-substituted heterobicyclic compounds PFIZER INC. (US) 2008-05-06 US disclosed
US-20070093525-A1 Triamide-substituted heterobicyclic compounds PFIZER INC 2007-04-26 US disclosed
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS BERTINATO PETER 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223851-A1 TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS APOB, MTPN, CTRB1 GBA1 426/4885TP53 4013/4885MAPT 3215/4885
US-20070093525-A1 Triamide-substituted heterobicyclic compounds APOB, MTPN, CTRB1 GBA1 426/4885TP53 4013/4885MAPT 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.